FREMONT, Calif., Feb. 27, 2017 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX), a late-stage clinical company focused on enhancing
the treatment of patients with cardiorenal and gastrointestinal
(GI) diseases, today announced that Mike
Raab, chief executive officer of Ardelyx, will present at
the Cowen and Company 37th Annual Healthcare Conference
on Monday, March 6, 2017 from 4:00 –
4:30 p.m. ET at the Boston Marriott
Copley Place.
To access the live webcast of Ardelyx's presentation, please
visit the Events & Presentations page within the Investor page
of the Ardelyx website at ir.ardelyx.com. A replay of the webcast
will be available on the Ardelyx website for 30 days following the
conference.
About Ardelyx, Inc.
Ardelyx is focused on enhancing the way patients with
cardiorenal and gastrointestinal (GI) diseases are treated by using
the gut as the gateway to delivering medicines that matter. The
company has established unique cardiorenal and GI business units
aimed at bringing new, effective medicines with distinct safety and
dosing advantages to underserved patients. Ardelyx's cardiorenal
portfolio includes the Phase 3 development of tenapanor for the
treatment of hyperphosphatemia in people with end-stage renal
disease who are on dialysis and the Phase 3 development of RDX7675
for the treatment of people with hyperkalemia. The company's GI
portfolio includes the Phase 3 development of tenapanor for the
treatment of people with irritable bowel syndrome with constipation
(IBS-C), and RDX8940, a TGR5 agonist approaching Phase 1
development. Leveraging the company's platform and unique
gut-restriction chemistry, Ardelyx intends to build a fully
integrated, revenue-generating biopharmaceutical company with
leading cardiorenal and GI business units. For more information,
please visit www.ardelyx.com and connect with us on Twitter
@Ardelyx.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ardelyx-announces-presentation-at-cowen-and-company-37th-annual-healthcare-conference-300414210.html
SOURCE Ardelyx